Oppenheimer analyst Martin Yang downgrades GoPro (NASDAQ:GPRO) from Outperform to Perform.
Enveric Biosciences’ Revenue Drops In Q3 2023 As Next-Gen Psychedelics Advance To Clinical Trials
Enveric Biosciences (NASDAQ: ENVB), a biopharma company developing novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, reported its financials for Q3 2023 ended September 30, 2023, showing: